Update on ventilator-associated pneumonia

Current Opinion in Critical Care
Cristina Vazquez Guillamet, Marin H Kollef

Abstract

To highlight the importance of escalating pathogen resistance in ventilator-associated pneumonia (VAP) along with diagnostic and treatment implications. In a period of rising bacterial resistance, VAP remains an important infection occurring in critically ill patients. Risk factors for multidrug-resistant pathogens depend on both local epidemiology and host factors. New diagnostic techniques and antimicrobials can help with rapid bacterial identification and timely and appropriate treatment while avoiding emergence of bacterial resistance. Clinicians should be aware of risk factors for multidrug-resistant pathogens causing VAP and also of particularities of diagnosis and treatment of this important clinical entity.

References

May 24, 2001·American Journal of Respiratory and Critical Care Medicine·P J DennesenM J Bonten
Apr 6, 2002·American Journal of Respiratory and Critical Care Medicine·Jean Chastre, Jean-Yves Fagon
Nov 20, 2002·Biomedical Engineering Online·Ritaban DuttaPascal Boilot
Nov 20, 2003·JAMA : the Journal of the American Medical Association·Jean ChastreUNKNOWN PneumA Trial Group
Jun 19, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David L PatersonVictor L Yu
Feb 9, 2005·American Journal of Respiratory and Critical Care Medicine·UNKNOWN American Thoracic Society, UNKNOWN Infectious Diseases Society of America
Oct 11, 2005·Critical Care Medicine·Nasia SafdarSanjay Saint
Feb 20, 2007·Antimicrobial Agents and Chemotherapy·Chonghua LiDavid P Nicolau
Sep 1, 2007·Current Opinion in Critical Care·Johan W Mouton, Alexander A Vinks
Jan 18, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Kara B AnthonyEbbing Lautenbach
Apr 19, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Michael KlompasRichard Platt
Sep 9, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Marin H Kollef
Apr 23, 2009·Critical Care Medicine·Jason A RobertsJeffrey Lipman
Aug 22, 2009·American Journal of Respiratory and Critical Care Medicine·Ricard FerrerUNKNOWN Edusepsis Study Group
Jun 19, 2010·Chest·Nadia Z HaqueUNKNOWN Improving Medicine through Pathway Assessment of Critical Therapy of Hospital-Acquired Pneumonia (IMPACT-HAP) Investigators
Jul 6, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ronald N Jones
Aug 6, 2010·International Journal of Antimicrobial Agents·Jason A RobertsJeffrey Lipman
Sep 16, 2010·European Journal of Clinical Investigation·Lee HumphreysCatherine A Kendall
Sep 18, 2010·Diagnostic Microbiology and Infectious Disease·Antonio T FreireUNKNOWN 311 Study Group
Oct 13, 2010·The Journal of Trauma·M MagretUNKNOWN EU-VAP/CAP Study Group
Dec 15, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ethan RubinsteinUNKNOWN ATTAIN Study Group
Mar 23, 2011·Antimicrobial Agents and Chemotherapy·Catharine C Bulik, David P Nicolau
Aug 20, 2011·American Journal of Respiratory and Critical Care Medicine·Maarten BekaertUNKNOWN Outcomerea Study Group
Sep 17, 2011·American Journal of Respiratory and Critical Care Medicine·Doo Ryeon ChungUNKNOWN Asian Network for Surveillance of Resistant Pathogens Study Group
Nov 24, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Stefano AlibertiFrancesco Blasi
Dec 14, 2011·PloS One·John R WaldeisenLuke P Lee
Jan 11, 2012·International Journal of Antimicrobial Agents·Giuseppe ValenzaUNKNOWN COMPACT Germany Study Group
Jan 17, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Richard G WunderinkJean Chastre
Feb 9, 2012·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Marin H KollefFrank R Ernst
Apr 3, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Paritosh PrasadCharles Natanson

❮ Previous
Next ❯

Citations

Feb 9, 2017·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Hung-Jen TangChih-Cheng Lai
Aug 21, 2018·Current Opinion in Critical Care·Milagros Dianti, Carlos M Luna
Feb 14, 2018·The European Respiratory Journal·Anne-Sophie MoreauUNKNOWN TAVeM Study Group
Jul 2, 2019·American Journal of Respiratory and Critical Care Medicine·Josef PrazakMatthias Haenggi
Apr 25, 2020·Expert Review of Anti-infective Therapy·Masako Mizusawa, Karen C Carroll
May 30, 2019·Antimicrobial Resistance and Infection Control·Rami SommersteinMarkus Hilty
Jun 27, 2019·Expert Review of Anti-infective Therapy·Adamantia LiapikouAntoni Torres
Nov 2, 2019·Lung India : Official Organ of Indian Chest Society·Gopi C KhilnaniRandeep Guleria

❮ Previous
Next ❯

Methods Mentioned

BETA
PCRs
PCR
bronchoalveolar lavage

Software Mentioned

IIAT

Related Concepts

Related Feeds

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

© 2021 Meta ULC. All rights reserved